Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: Evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 112-126

  Smith, Charles A ^a   Pollice, Agnese A ^a   Gu, Ling Ping ^a   Brown, Kathryn A ^a   Singh, Sarita G ^a   Janocko, Laura E ^a   Johnson, Ronald ^a   Julian, Thomas ^a   Hyams, David ^a   Wolmark, Norman ^a   Sweeney, Lillian ^a   Silverman, Jan F ^a   Shackney, Stanley E ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RAS PROTEIN;

ALLELE; ANEUPLOIDY; ARTICLE; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTRADUCTAL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

ANEUPLOIDY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DIPLOIDY; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENES, ERBB-2; GENES, P53; GENES, RAS; HUMANS; LOSS OF HETEROZYGOSITY; PHENOTYPE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033971807     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Shackney, S., Pollice, A., Smith, C., Alston, L., Singh, S., Janocko, L., Brown, K., Petruolo, S., Groft, D., Yakulis, R., and Hartsock, R. The accumulation of multiple genetic abnormalities in individual tumor cells in human breast cancers: clinical prognostic implications. Cancer J., 2: 105-114, 1996.
2. ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. Clin. Cancer Res., 4: 913-918, 1998.
3. Shackney, S., and Shankey, T. Common patterns of genetic evolution in human solid tumors. Cytometry, 29: 1-27, 1997.
4. Donehower, L. Genetic instability in animal tumorigenic models. Cancer Surv., 29: 329-352, 1997.
5. Berger, M., Locher, G., Saurer, S., Gullick, W., Waterfield, M., Groner, B., and Hynes, N. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res., 48: 1238-1243, 1988.
6. Seshadri, R., Leong, A-Y., McCaul, K., Firgaira, F., Setlur, V., and Horsfall, D. Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis. Int. J. Cancer, 69: 135-141, 1996.
7. HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res., 55: 5400-5407, 1995.
8. Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H., and Sigurdsson, H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene, 6: 137-143, 1991.
9. Ciocca, D., Fujimura, F., Tandon, A., Clark, G., Mark, C., Lee-Chen, G-J., Pounds, G., Vendely, P., Owens, M., Pandian, M., and McGuire, W. Correlation of Her-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J. Natl. Cancer Inst., 84: 1279-1281, 1992.
10. Tavassoli, M., Quirke, P., Farzaneh, F., Lock, N., Mayne, L., and Kirkham, N. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br. J. Cancer, 60: 505-510, 1989.
11. Shackney, S., Smith, C., Pollice, A., Janocko, L., Singh, S., Groft, D., Brown, K., and Hartsock, R. Preferred genetic evolutionary sequences in human breast cancer: a case study. Cytometry, 21: 6-13, 1995.
12. Pollice, A., McCoy, J., Shackney, S., Smith, C., Agarwal, J., Burholt, D., Janocko, L., Hornicek, F., Singh, S., and Hartsock, R. Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. Cytometry, 13: 432-444, 1992.
13. Brotherick, I., Shenton, B., Cowan, W., Angus, B., Horne, C., Higgs, M., and Lennard, T. p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship between grade and DNA ploidy in breast cancer. Cancer Immunol. Immunother., 41: 146-150, 1995.
14. Filippini, G., Griffin, S., Uhr, M., Eppenberger, H., Bonilla, J., Cavalli, F., and Soldati, G. A novel flow cytometric method for the quantification of p53 expression. Cytometry, 31: 180-186, 1998.
15. Kibbelaar, R., Kok, F., Dreef, E., Kleiverda, J., Cornelisse, C., Raap, A., and Kluin, P. Statistical methods in interphase cytogenetic studies. Cytometry, 14: 716-724, 1993.
16. Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Rejthar, A., Kovarik, J., and Lane, D. Patterns of expression of p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int. J. Cancer, 46: 839-844, 1990.
17. Horak, E., Smith, K., Bromley, L., LeJeune, S., Greenall, M., Lane, D., and Harris, A. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene, 6: 2277-2284, 1991.
18. Isola, J., Visakorpi, T., Holli, K., and Kallionemi, O-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst., 84: 1109-1114, 1992.
19. Thor, A., Moore, D., II, Edgerton, S., Kawasaki, E., Reihsaus, E., Lynch, H., Marcus, J., Schwartz, L., Chen, L-C., Mayall, B., and Smith, H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
20. Poller, D., Hutchings, C., Galea, M., Bell, J., Nicholson, R., Elston, C., Blamey, R., and Ellis, I. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br. J. Cancer, 66: 583-588, 1992.
21. Elledge, R., Clark, G., Fuqua, S., Yu, Y-Y., and Allred, D. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res., 54: 3752-3757, 1994.
22. Haerslev, T., and Jacobsen, G. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum. Pathol., 26: 295-301, 1995.
23. Visscher, D., Sarkar, F., Shimoyama, R., and Crissman, J. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn. Mol. Pathol., 5: 187-193, 1996.
24. Silvestrini, R., Benini, E., Veneroni, S., Daidone, M., Tomasic, G., Squicciarini, P., and Salvadori, B. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol., 14: 1604-1610, 1996.
25. O'Malley, F., Saad, Z., Kerkvliet, N., Doig, G., Stitt, L., Ainsworth, P., Hundaal, H., Chambers, A., Turnbull, D., and Bramwell, V. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum. Pathol., 27: 955-963, 1996.
26. Sjogren, S., Ingandas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-182, 1996.
27. Venkatachalam, S., Shi, Y., Jones, S., Vogel, H., Bradley, A., Pinkel, D., and Donehower, L. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J., 17: 4657-4667, 1998.
28. Gullick, W. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int. J. Cancer, 5(suppl.): 55-61, 1990.
29. Hall, P., and Lane, D. p53 in tumour pathology: can we trust immunohistochemistry? - revisited! J. Pathol., 172: 1-4, 1994.
30. Lane, D., and Hall, P. MDM2-Arbiter of p53's destruction. Trends Biochem. Sci., 22: 372-374, 1997.
31. Midgley, C., and Lane, D. p53 protein stability in tumor cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene, 15: 1179-1189, 1997.
32. Moll, U., Riou, G., and Levine, A. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262-7266, 1992.
33. Stenmark-Askmalm, M., Sullivan, S., Ferraud. L., Sun, X., Carstensen, J., and Nordenskjold, B. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur. J. Cancer, 30A: 175-180, 1994.
34. Momand, J., and Zambetti, G. Mdm-2: "big brother" of p53. J. Cell. Biochem., 64: 343-352, 1997.
35. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell, 95: 5-8, 1998.
36. Gunther, T., Schneider-Stock, R., Rys, J., Niezabitowski, A., and Roessner, A. p53 gene mutations and expression of p53 and mdni2 proteins in invasive breast carcinoma. J. Cancer Res. Clin. Oncol., 123: 388-394, 1997.
37. Read, L., Keith, J., Slamon, D., and Katrzenellenbogen, B. Hormonal modulation of Her-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res., 50: 3947-3951, 1990.
38. De Bortoli, M., Dati, C., Anroniotti, S., Maggiora, P., and Sapei, M. Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. J. Steroid Biochem. Mol. Biol., 43: 21-25, 1992.
39. Yu, D., Matin, A., and Hung, M-C. The retinoblastoma gene product suppresses neu oncogene-induced transformation via transcriptional repression of neu. J. Biol. Chem., 267: 10203-10206, 1992.
40. Theillet, C., Lidereau, R., Escot, C., Hutzell, P., Brunet, M., Gest, J., Schlom, J., and Callahan, R. Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res., 46: 4776-4781, 1986.
41. Garcia, I., Dietrich, P., Aapro, M., Vauthier, G., Vadas, L., and Engel, E. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protoon-cogenes and clinical associations in human breast carcinomas. Cancer Res., 49: 6675-6679, 1989.
42. Rochlitz, C., Scott, G., Dodson, J., Liu, E., Dollbaum, C., Smith, H., and Benz, C. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res., 49: 357-360, 1989.
43. Cross, S., Sanchez, C., Morgan, C., Schimke, M., Ramel, S., Idzerda, R., Raskind, W., and Reid, B. A p53-dependent mouse spindle checkpoint. Science (Washington DC), 267: 1353-1356, 1995.
44. L and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev., 10: 2621-2631, 1996.
45. Di Leonardo, A., Khan, S., Linke, S., Greco, V., Seidita, G., and Wahl, G. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res., 57: 1013-1019, 1997.
46. Fukasawa, K., Weiner, F., Vande Woude, G., and Mai, S. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene, 75: 1295-1302, 1997.
47. Bischoff, F., Yim, S., Pathak, S., Grant, G., Siciliano, M., Giovanella, B., Strong, L., and Tainsky, M. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res., 50: 7979-7984, 1990.
48. 2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ., 8: 1105-1114, 1997.
49. Livingstone, L., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tisty, T. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
50. Lengauer, C., Kinzler, K., and Vogelstein, B. Genetic instabilities in human cancers. Nature (Lond.), 396: 643-649, 1998.
51. Hinds, P., Finlay, C., and Levine, A. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol., 63: 739-746, 1989.
52. Hicks, G., Egan, S., Greenberg, A., and Mowat, M. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol. Cell. Biol., 11: 1344-1352, 1991.
53. Lin, H-J., Eviner, V., Prendergast, G., and White, E. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell. Biol., 15: 4536-4544, 1995.
54. INK4a. Cell, 88: 593-602, 1997.
55. ARF lins the tumor suppressor p53 to Ras. Nature (Lond.), 395: 125-126, 1998.
56. Fisher, E., Costantino, J., Fisher, B., Palekar, A., Paik, S., Suarez, C., and Wolmark, N. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Cancer (Phila.), 78: 1403-1416, 1996.
57. Walker, R., Dearing, S., Lane, D., and Varley, J. Expression of p53 protein in infiltrating and in situ breast carcinomas. J. Pathol., 765: 203-211, 1991.
58. Domagala, W., Markiewski, M., Kubiak, R., Bartkowiak, J., and Osborn, M. Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch. A Pathol. Anat. Histopathol., 423: 497-502, 1993.
59. Rosen, P., Lesser, M., Arroyo, C., Cranor, M., Borgen, P., and Norton, L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiological risk factors, histologic features, and prognosis. J. Clin. Oncol., 13: 821-830, 1995.
60. Parkes, H., Lillycrop, K., Howell, A., and Craig, R. c-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br. J. Cancer, 61: 39-45, 1990.
61. Antoniades, K., and Spector, H. Correlation of estrogen receptor levels with histology and cytomorphology in human mammary cancer. Am. J. Clin. Pathol., 71: 497-503, 1979.